The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the mrna cancer vaccines and therapeutics market further?
The rise in the prevalence of cancer is expected to propel the growth of the mRNA cancer vaccine and therapeutic market going forward. Cancer is a broad term for a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, that invade and destroy normal body tissue. The rise in the prevalence of cancer is due to sedentary lifestyles, unhealthy eating habits, and exposure to environmental toxins. mRNA cancer vaccines and therapeutics are required for cancer because they offer personalized, targeted treatments that can enhance the immune system’s ability to recognize and attack cancer cells, improving treatment efficacy and patient outcomes. For instance, in January 2023, according to the data published by the American Cancer Society, a US-based non-profit organization working to eliminate cancer, the estimated number of new cancer cases in the United States, was around 1,918,030 in 2022, which increased to 1,958,310 in 2023. Breast cancer is the leading chronic condition in the United States, increasing from 287,850 cases in 2022 to 297,790 cases in 2023, respectively. Therefore, the rise in the prevalence of cancer is driving the growth of the mRNA cancer vaccine and therapeutics market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=17204&type=smp
What are the key factors influencing the forecasted market size of the mrna cancer vaccines and therapeutics industry?
The mRNA cancer vaccines and therapeutics market size has grown rapidly in recent years. It will grow from $61.52 billion in 2024 to $71.85 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to the shifting lifestyles, the funding support, the favorable regulatory environment, the well-established healthcare infrastructure, and increasing pipeline development.
The mRNA cancer vaccines and therapeutics market size is expected to see rapid growth in the next few years. It will grow to $131.99 billion in 2029 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to promising clinical trial results, growing awareness and acceptance of mRNA technology, unmet medical needs in cancer treatment, potential for improved patient outcomes and potential for off-the-shelf availability. Major trends in the forecast period include expansion into new therapeutic areas, personalized medicine approach, advancements in mRNA delivery systems, multivalent mRNA Vaccines and artificial intelligence and machine learning in mRNA design.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=17204&type=smp
Who are the leading competitors in the mrna cancer vaccines and therapeutics market?
Major companies operating in the mRNA cancer vaccines and therapeutics market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, Sanofi AG, AstraZeneca Plc, GlaxoSmithKline Plc, Hoffmann-La Roche AG, Eli Lilly and Company, Moderna Therapeutics Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Catalent Inc., Sarepta Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Genentech Inc., Immatics Biotechnologies GmbH, CureVac N.V, Anima Biotech, Argos Therapeutics Inc.
Which emerging trends are set to transform the mrna cancer vaccines and therapeutics market landscape?
Major players operating in the mRNA cancer vaccine and therapeutics market are focused on the development of innovative treatments such as mRNA cancer vaccines to enhance efficacy, improve patient outcomes, and address the growing demand for effective cancer therapies. mRNA cancer vaccines are a type of immunotherapy that use messenger RNA to instruct cells to produce specific antigens, thereby stimulating the immune system to recognize and attack cancer cells. For instance, in May 2024, WestGene Biopharma, a China-based, biotechnology company received FDA approval for an investigational new drug application of its mRNA therapeutic cancer vaccine, WGc-043. The FDA approval of WGc-043 marks a breakthrough in treating advanced EB virus-related cancers, which are strongly linked to over ten malignancies, including nasopharyngeal carcinoma, NK T-cell lymphoma, and gastric, lung, liver, esophageal, breast, and cervical cancers, as well as autoimmune diseases such as multiple sclerosis and lupus.
How do different geographies compare in terms of market share and growth potential in the mrna cancer vaccines and therapeutics market?
North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mRNA cancer vaccines and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
Which major segments of the mrna cancer vaccines and therapeutics market are experiencing the fastest growth?
The mRNA cancer vaccines and therapeutics market covered in this report is segmented –
1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas
2) By Application: Infectious Disease, Cancer, Other Applications
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users
Subsegments:
1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas
2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer
3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17204
How is the mrna cancer vaccines and therapeutics market defined?
mRNA cancer vaccines and therapeutics refer to a type of medical treatment that utilizes messenger RNA (mRNA) to stimulate the immune system to recognize and fight cancer cells. It is used to deliver instructions to cells to produce therapeutic proteins or enzymes and help prime the immune system to identify and destroy cancer cells that express these antigens.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
